In:
Pakistan Postgraduate Medical Journal, Postgraduate Medical Institute, Lahore General Hospital, Vol. 30, No. 04 ( 2019-12-28), p. 139-141
Abstract:
Background: Type 2 diabetes mellitus (T2DM) is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia. Current guidelines for treating patients with T2DM are based on glycemic standards. Sitagliptin seems to maintain its positive effects on glycemia and fasting plasma insulin on the long term as compared to sulfonylurea. Objective: To compare the effectiveness of sitagliptin versus sulfonylurea for management of patients with type II diabetes mellitus Methods: it was randomized controlled trial. The data was collected in North medical ward, department of medicine Mayo hospital Lahore. The patients were randomly divided into two groups e.g Group A Sitagliptin and group B sulfonylurea. The blood sample were drawn at baseline and after 12 weeks for HbA1c level. Results: In Sitagliptin group, the mean age of patients was 57.93±13.10years. In sulfonylurea group, the mean age of patients was 63.51±11.23years. There were 35 (50.0%) male and 35 (50.0%) females in Sitagliptin group. There were 31 (44.3%) male and 39 (55.7%) females in sulfonylurea group. There was 1.19±1.00% decrease in HbA1c with sitagliptin and 0.53±0.31% with sulfonylurea. The difference was significant (p 〈 0.05). In our trial, effectiveness was achieved in 50 (71.4%) with sitagliptin while in 33 (47.1%) with sulfonylurea. The difference was significant (p 〈 0.05). Conclusion: Thus, Sitagliptin is more effective and control more HbA1c than sulfonylurea for management of T2DM
Type of Medium:
Online Resource
ISSN:
2710-1924
,
2079-5858
DOI:
10.51642/ppmj.v30i04
DOI:
10.51642/ppmj.v30i04.564
Language:
Unknown
Publisher:
Postgraduate Medical Institute, Lahore General Hospital
Publication Date:
2019
Permalink
